Scarica l'app Stockscreener
5.1199
5.03%
0.2449
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks
ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - PR Newswire
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace
ImmunityBio announces new data from QUILT 3.032 study - TipRanks
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ImmunityBio Reports Third-Quarter 2024 Financial Results - The Bakersfield Californian
(IBRX) Technical Pivots with Risk Controls - Stock Traders Daily
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3%Should You Sell? - MarketBeat
Why ImmunityBio Stock Is Trading Higher Thursday - MSN
Commit To Buy ImmunityBio At $4, Earn 25% Using Options - Nasdaq
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes - Law360
Penny Stock Trades: Joby Aviation and ImmunityBio - Baystreet.ca
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6%Here's Why - MarketBeat
(IBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - TipRanks
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025 - Seeking Alpha
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume – Still a Buy? - Defense World
ImmunityBio Stock Heats Up, Catches Retail's Eye On Cancer Drug Trial Progress And Analyst’s Bullish Call - Barchart
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
ImmunityBio stock jumps after trial update (IBRX:NASDAQ) - Seeking Alpha
Stock Traders Buy High Volume of ImmunityBio Call Options (NASDAQ:IBRX) - MarketBeat
EF Hutton sees over 600% upside in biotech small cap ImmunityBio - Kursiv Media
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
ImmunityBio (IBRX) Stock Extends Pre-Hour Rally Following Clinical Trial News - Stocks Telegraph
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL - Yahoo! Voices
ImmunityBio begins dosing in Phase 1 trial of CAR-NK therapy for relapsed NHL - World Pharmaceutical Frontiers
ImmunityBio (NASDAQ:IBRX) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I - Defense World
ImmunityBio (NASDAQ:IBRX) Trading 7.8% HigherHere's What Happened - MarketBeat
ImmunityBio Stock Could Rocket 800%, Analyst Says - Barron's
This Biotech Stock Could Rocket 800%, Analyst Says - MSN
ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL - TipRanks
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma - Business Wire
ImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I - MarketBeat
800% Upside For This Biotech StockAnalyst Initiates Coverage On Bladder Cancer Focused ImmunityBio - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's What Happened - MarketBeat
EF Hutton sets stock target with buy rating for ImmunityBio, cites cancer therapy - Investing.com
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):